Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Aug '25 Aug 12, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Market Capitalization	140	80	92	118	120	31	Upgrade
Market Cap Growth	8.10%	-12.77%	-21.95%	-1.79%	293.11%	1179.47%	Upgrade
Enterprise Value	164	102	108	130	126	26	Upgrade
Last Close Price	0.29	0.17	0.26	0.37	0.50	0.28	Upgrade
PS Ratio	1.23	0.74	1.05	2.36	23.04	-	Upgrade
PB Ratio	9.11	4.34	6.46	2.68	3.08	3.13	Upgrade
P/TBV Ratio	9.11	4.34	6.46	2.68	3.08	3.13	Upgrade
EV/Sales Ratio	1.44	0.94	1.24	2.61	24.25	-	Upgrade
EV/EBITDA Ratio	10.09	14.33	-	-	-	-	Upgrade
Debt / Equity Ratio	1.76	1.17	1.63	0.63	0.28	0.00	Upgrade
Debt / EBITDA Ratio	1.66	3.04	-	-	-	-	Upgrade
Asset Turnover	1.09	1.02	0.82	0.54	0.14	-	Upgrade
Inventory Turnover	14.72	15.68	17.03	13.35	-	-	Upgrade
Quick Ratio	0.37	0.38	0.39	0.63	0.84	21.26	Upgrade
Current Ratio	0.55	0.57	0.53	0.82	1.13	22.33	Upgrade
Return on Equity (ROE)	-164.81%	-147.28%	-147.52%	-84.57%	-61.63%	-37.20%	Upgrade
Return on Assets (ROA)	0.35%	-5.95%	-17.00%	-18.71%	-22.06%	-20.98%	Upgrade
Return on Capital (ROIC)	0.92%	-15.63%	-33.94%	-27.71%	-27.65%	-22.01%	Upgrade
Earnings Yield	-12.63%	-31.20%	-45.84%	-30.73%	-12.49%	-7.18%	Upgrade
FCF Yield	-6.38%	-15.86%	-16.32%	-21.20%	-24.14%	-9.40%	Upgrade
Buyback Yield / Dilution	-26.09%	-20.30%	-31.03%	-39.53%	-127.01%	-97.26%	Upgrade

Updated Nov 22, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.